MWM
BIVV

Mascoma Wealth Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Mascoma Wealth Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20
Closed -$1K – 428
2017
Q2 		$1K Buy
+20
New +$1.14K ﹤0.01% 400

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Mascoma Wealth Management's BIVV Position: Q3 2017 in Review

Mascoma Wealth Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q3 2017, closing a stake of 20 shares — an estimated $1K sold.

Mascoma Wealth Management first reported a position in BIVV in Q2 2017 and held it in 1 quarter. The position peaked at $1K in Q2 2017. 446 funds tracked by Wall St. Rank hold BIVV as of Q3 2017.

  • Mascoma Wealth Management reported no remaining Bioverativ Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Mascoma Wealth Management sold 20 Bioverativ Inc. Common Stock shares in Q3 2017, an estimated $1K.
  • Mascoma Wealth Management first reported a position in Bioverativ Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Mascoma Wealth Management's Bioverativ Inc. Common Stock position peaked at $1K in Q2 2017.
  • 446 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q3 2017.

Based on Mascoma Wealth Management's 13F filing for Q3 2017, filed 7 Nov 2017.